Parkinson Disease
Conditions
Brief summary
Parkinson's disease is a progressive neurodegenerative disease that causes disabling motor and cognitive impairments. Currently, no disease-modifying therapy exists for this disease. Mannitol, a naturally-occurring substance, which is commonly used as sweetener, was offered as such agent. In this phase II, safety, tolerability-based dose finding, and efficacy study, mannitol or placebo (dextrose) in escalating doses will be given to patients with Parkinson's disease for 36 weeks.
Interventions
DIETARY_SUPPLEMENTOral D-Mannitol of Placebo
Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
Sponsors
Hadassah Medical Organization
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Ability to understand and signing of informed consent form. 2. Age 40-75 years at the day of visit 1. 3. Diagnosis of Parkinson's disease that is based on the United Kingdom brain bank criteria diagnosed after the age of 40. 4. Stable regime of anti-parkinsonian medication for at least 4 weeks at the day of visit 1.
Exclusion criteria
1. Patients with motor deficits that require administration of symptomatic therapy more than 4 times per day at the day of visit 1. 2. Patients on advanced therapy for Parkinson's disease (sub-cutaneous apomorphine, deep brain stimulation or intra-jejunal levodopa infusion). 3. Patients with dementia reflected by a Mini-mental state examination (MoCA) ≥ 24. 4. Patient with legal guardian. 5. History of psychosis or use of dopamine receptor blocking agent on the year proceeding at the visit 1. Quetiapine at dose lower or equal 50 mg per day prescribed for indication other than psychosis is allowed. 6. Suspected Parkinsonian syndrome other than Parkinson's disease. 7. Use of medical marihuana on the month proceeding visit 1. 8. Pregnant or lactating women, or fertile woman who does not use contraceptive. Woman of child-bearing potential must have a negative urine Human chorionic gonadotropin (hCG) and will be monitored by repeated urine tests. 9. Patient with significantly impaired renal functions (urea or creatinine values 20% above the upper norm limit). 10. Diabetes mellitus. 11. Clinical evidence for congestive heart failure. 12. Patient with symptomatic orthostatic hypotension. 13. Based on investigator's opinion, any medical condition that may progress due to consumption of oral mannitol or glucose.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of oral mannitol in Parkinson's disease as assessed by the number of mannitol-related adverse events, clinically significant changes in vital signs and clinically significant abnormalities in laboratory results. | 36 weeks | Safety will be assessed by the number of treatment-related adverse events, number of patients with clinically significant change of vital signs (supine and standing blood pressure and pulse) and number of patients with clinically significant change in laboratory results (electrolytes, renal and liver functions, blood count). |
| Tolerability of oral mannitol in Parkinson's disease as assessed by the maximal daily dose (in grams) of mannitol that does not cause discomfort. | 36 weeks | Tolerability of oral mannitol in Parkinson's disease as assessed by the maximal daily dose (in grams, up to 18 grams per day) of mannitol that does not cause discomfort based on the subjective report by the patient. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of Brief Smell Identification Test (B-SIT) score between baseline and week 36. | 36 weeks | Median and range of change will be reported. P-Values as assessed by Mann-Whitney test will be reported. Higher absolute positive value (reflecting improved smell) or lower absolute negative value (slower deterioration) will be considered as better outcomes. |
| Change in constipation assesment (CAS) score between baseline and week 36. | 36 weeks | Median and range of change will be reported. Change in score will be reported. P-Values as assessed by Mann-Whitney test will be reported. Lower absolute positive value or higher absolute negative value will be considered as better outcomes. |
| Time-interval for starting symptomatic therapy (in days) between baseline and week 36, in patients not receiving symptomatic therapy at baseline. | 36 weeks | Median time interval will be reported. P-Values as assessed by Mann-Whitney test will be reported. Longer time interval will be considered as a better outcome. |
| Change in non-motor symptoms of Parkinson's disease scale (NMSS) between baseline and week 36. | 36 weeks | Median and range of change will be reported. P-Values as assessed by Mann-Whitney test will be reported. Lower absolute positive value or higher absolute negative value will be considered as better outcomes. |
| Change in the ratio of total-to-proteinase K-resistant α-synuclein in red blood cells (RBC) measured by enzyme-linked immunosorbent assay (ELISA)between baseline and week 36. | 36 weeks | Median and range of change will be reported. P-Values as assessed by Mann-Whitney test will be reported. Higher absolute positive value or lower absolute negative value will be considered as better outcomes. |
| Change in Montreal Cognitive Assessment (MoCA) test score between baseline and week 36. | 36 weeks | P-Values as assessed by Mann-Whitney test will be reported. Higher absolute positive value or lower absolute negative value will be considered as better outcomes. |
| Change in levodopa-equivalent dose units between baseline and week 36. | 36 weeks | Total levodopa-equivalent dose (LED units) will be calculated based on Tomlinson, Mov Disord 2010. P-Values as assessed by Mann-Whitney test will be reported. Smaller change will be considered as a better outcome. |
Countries
Israel
Contacts
Primary ContactDavid Arkadir, MD PhD
Backup ContactAnna Linetsky
Outcome results
None listed